Misdiagnosis and Barriers to Early Detection of IgAN

Author(s):

Jonathan Barratt, PhD, FRCP,Anuja Java, MD

Key Takeaways

IgA nephropathy diagnosis is hindered by nonspecific symptoms and the necessity of a kidney biopsy for confirmation.
Misdiagnosis or delayed diagnosis arises from symptom overlap with other renal conditions, such as hematuria and proteinuria.
Limited awareness among healthcare providers and variability in disease presentation contribute to diagnostic challenges.
Enhancing awareness, access to diagnostic tools, and developing non-invasive biomarkers are crucial for improving early detection and patient outcomes.

Panelists discuss how misdiagnosis and delayed diagnosis of IgA nephropathy occur, highlighting the primary barriers to timely detection and strategies to overcome these challenges.

EP: 1.Overview of IgAN and Its Common Symptoms

EP: 2.IgAN Progression

EP: 3.IgAN vs Other Glomerular Diseases

EP: 4.Biomarkers for IgAN

EP: 5.Genetic Screening for IgAN

EP: 6.Impact of IgAN on Quality of Life

Now Viewing

EP: 7.Misdiagnosis and Barriers to Early Detection of IgAN

EP: 8.Differential Diagnoses of IgAN

EP: 9.Significance of Proteinuria for Potential IgAN

EP: 10.Proteinuria Variability and IgAN Diagnosis

EP: 11.Biomarkers and Improving IgAN Diagnostic Accuracy

EP: 12.Primary Treatment Goals for Patients With IgAN

Please discuss misdiagnosis and delayed diagnosis as it relates to IgAN? IgA nephropathy.
1. What are some of the primary barriers to timely detection of the disease, and how can these be addressed?